Comparative Pharmacology
Head-to-head clinical analysis: LOCOID versus VANOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOCOID versus VANOS.
LOCOID vs VANOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
VANOS (fluocinonide 0.1% cream) is a corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2 and reduction of prostaglandin and leukotriene synthesis, resulting in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical: Apply a thin layer to affected area once or twice daily. Maximum: 30-60 g per week. Not for use >2 consecutive weeks or on >50% of body surface.
Apply a thin layer to affected areas once or twice daily. Not for use longer than 2 weeks; maximum 15 g per day.
None Documented
None Documented
Terminal elimination half-life: 30-40 hours; clinically significant for once-daily dosing and prolonged action
The terminal elimination half-life is approximately 7.5 hours (range 5-12 hours). This supports twice-daily or once-daily dosing for sustained local effect.
Renal (approximately 60-70%) as conjugated metabolites; biliary/fecal (approximately 20-30%)
Primarily renal excretion (glucuronidation and sulfation); minimal biliary elimination (<5%). Approximately 60-70% of the dose is excreted in urine as metabolites, with <1% unchanged.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid